Evidence map›Paper›PMID 14675704›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2003

18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma.

Cosimo Sperti, Claudio Pasquali, Franca Chierichetti, Andrea Ferronato, Giandomenico Decet, Sergio Pedrazzoli

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Incidental analWorld journal of clinical cases · 2020
    Article
  11. Article
  12. Article
  13. Optimal respiratory-gated [EJNMMI research · 2019
    Article
  14. Cancer medicine · 2018
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Cosimo SpertiDepartment of Medical and Surgical Sciences, Section of Semeiotica Chirurgica, Ospedale Busonera, University of Padova, Padua, Italy.
Claudio Pasquali
Franca Chierichetti
Andrea Ferronato
Giandomenico Decet
Sergio Pedrazzoli
University of Padua · ITOspedaliero di Castelfranco Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prediction of survival of patients with pancreatic cancer is usually based on tumor staging and grading and on the level of tumor markers. However, accurate tumor staging can be obtained only after resection, and still there is a great difference in survival rates among patients with the same clinicopathologic parameters. Recently the uptake of 18-fluorodeoxyglucose (FDG) by positron emission tomography (PET) has been found to be correlated with survival in patients with pancreatic cancer. This study evaluated the role of 18FDG PET as a prognostic factor for patients with pancreatic cancer. From June 1996 to July 2002, a total of 118 patients underwent PET for pancreatic cancer. The standardized uptake value (SUV) of 18FDG was calculated in 60 of them, and these patients were divided into high (>4) and low (< or =4) SUV groups. They were also evaluated according to the tumor node metastasis (TNM) classification system of the International Union Against Cancer, and by tumor grade, medical or surgical treatment, diabetes, age, sex, and CA 19-9 serum levels. Twenty-nine cancers showed high and 31 showed low SUVs. Survival was significantly influenced by tumor stage (P=0.0001), tumor grade (P=0.01), and SUV (P=0.005). Multivariate analysis showed that only stage (P=0.001) and SUV (P=0.0002) were independent predictors of survival. When patients who were analyzed for SUV were stratified according to the other variables, FDG uptake was related to survival also after stratification for the following: stage III to IVa (P=0.002), stage IVb (P=0.01), tumor resection (P=0.006), moderately differentiated tumors (P=0.01), age less than 65 years (P=0.006), CA 19-9 levels greater than 300 kU/L (P=0.002), and absence of diabetes (P=0.0001). The SUV calculated with 18FDG PET is an important prognostic factor for patients with pancreatic cancer and may be useful in selecting patients for therapeutic management.

Indexed as

Fluorodeoxyglucose F18RadiopharmaceuticalsAdenocarcinomaAgedAged, 80 and overFemaleGlucoseHumansMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsPrognosisSurvival AnalysisTomography, Emission-ComputedFluorodeoxyglucose F18GlucoseRadiopharmaceuticals

Identifiers

PMID14675704
OpenAlexW2071121228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.